Actelion's ambitious independent-minded CEO will drive up takeover price

ZURICH, Nov 28 (Reuters) - Actelion Chief Executive

Jean-Paul Clozel's desire to keep Europe's biggest biotech

company independent after building it from scratch, means

Johnson & Johnson will have to...

Read more